Journal of Developing Drugs
Open Access

Abstract

Repurposing FDA-Approved Drugs for Neurodegenerative Disorders: A Computational and Experimental Approach

Mariana Costa Oliveira*

Neurodegenerative disorders such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS) continue to pose a major global health burden, with limited effective treatments available. Traditional drug development for these conditions has been slow and costly, with high failure rates during clinical trials. In light of this challenge, drug repurposing identifying new therapeutic uses for already- approved medications has gained attention as a time- and cost- effective strategy. This study adopts a dual computational and experimental approach to identify FDA-approved drugs with potential efficacy in treating neurodegenerative diseases.

Published Date: 2025-03-04; Received Date: 2025-02-03